


Status: Currently Official on 14-Feb-2025
Official Date: Official as of 01-Aug-2022
Document Type: USP Monographs
DocId: GUID-7D8122C7-8455-42DA-B785-56C90D1B6E99_6_en-US
DOI: https://doi.org/10.31003/USPNF_M28010_06_01
DOI Ref: sm9m2

© 2025 USPC
Do not distribute

Dopamine Hydrochloride



$C_8H_{11}NO_2 \cdot HCl$ 189.64
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride;
4-(2-Aminoethyl)pyrocatechol hydrochloride CAS RN®: 62-31-7; UNII: 7L3E358N9L.

DEFINITION
Dopamine Hydrochloride contains NLT 98.0% and NMT 102.0% of dopamine hydrochloride ($C_8H_{11}NO_2 \cdot HCl$), calculated on the dried basis.

IDENTIFICATION

Change to read:

- **A. SPECTROSCOPIC IDENTIFICATION TESTS (197), Infrared Spectroscopy:** ▲197A or ▲(USP 1-Aug-2022) 197K

Delete the following:

- ▲ **B. SPECTROSCOPIC IDENTIFICATION TESTS (197), Ultraviolet-Visible Spectroscopy:** 197U

Sample solution: 40 µg/mL in *Medium*
Medium: Sodium bisulfite in water (1 in 1000)▲ (USP 1-Aug-2022)

Add the following:

- ▲ **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.▲ (USP 1-Aug-2022)
- **C. IDENTIFICATION TESTS—GENERAL (191), Chemical Identification Tests, Chloride:** Meets the requirements

ASSAY

Change to read:

• **PROCEDURE**

▲ **Buffer:** Dissolve 21 g of [citric acid](#) in 200 mL of 1 N [sodium hydroxide](#) in a 1-L flask. Dilute with [water](#) to volume. To 600 mL of this solution add 400 mL of 0.1 N hydrochloric acid.

Solution A: Dissolve 1.08 g of [1-octanesulfonic acid sodium salt](#) in 880 mL of *Buffer* in a 1-L flask. Add 50 mL of [methanol](#) and 70 mL of [acetonitrile](#).

Solution B: Dissolve 1.08 g of [1-octanesulfonic acid sodium salt](#) in 700 mL of *Buffer* in a 1-L flask. Add 100 mL of [methanol](#) and 200 mL of [acetonitrile](#).

Mobile phase: See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0.0	90	10
5.0	90	10
20.0	40	60
25.0	40	60
25.1	90	10
35.0	90	10

Standard solution: 0.5 mg/mL of [USP Dopamine Hydrochloride RS](#) in *Solution A*

Sample solution: 0.5 mg/mL of Dopamine Hydrochloride in *Solution A*

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 280 nm

Column: 3.9-mm × 15-cm; 4.0-μm packing [L1](#)

Flow rate: 1 mL/min

Injection volume: 10 μL

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2.5

Relative standard deviation: NMT 0.73%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of dopamine hydrochloride ($C_8H_{11}NO_2 \cdot HCl$) in the portion of Dopamine Hydrochloride taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of dopamine from the *Sample solution*

r_S = peak response of dopamine from the *Standard solution*

C_S = concentration of [USP Dopamine Hydrochloride RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Dopamine Hydrochloride in the *Sample solution* (mg/mL) ▲ (USP 1-Aug-2022)

Acceptance criteria: 98.0%–102.0% on the dried basis

IMPURITIES

• [RESIDUE ON IGNITION \(281\)](#): NMT 0.1%

• [CHLORIDE AND SULFATE \(221\)](#), *Sulfate*

Standard solution: 0.10 mL of [0.020 N sulfuric acid](#)

Sample solution: 500 mg of Dopamine Hydrochloride in 40 mL of [water](#)

Acceptance criteria: Any turbidity produced in the *Sample solution* is NMT that produced in the *Standard solution*.

Change to read:

• **ORGANIC IMPURITIES**

▲ **Buffer, Solution A, Solution B, Mobile phase, and Chromatographic system:** Proceed as directed in the Assay.

System suitability solution: 0.024 mg/mL each of [USP Dopamine Related Compound A RS](#) and [USP Dopamine Related Compound B RS](#) in *Solution A*

Sensitivity solution: 0.001 mg/mL of [USP Dopamine Hydrochloride RS](#) in *Solution A*

Standard solution: 0.002 mg/mL each of [USP Dopamine Hydrochloride RS](#), [USP Dopamine Related Compound A RS](#), [USP Dopamine Related Compound B RS](#), and [USP Dopamine Related Compound C RS](#) in *Solution A*

Sample solution: 2.0 mg/mL of Dopamine Hydrochloride in *Solution A*

System suitability

Samples: *System suitability solution*, *Sensitivity solution*, and *Standard solution*

[NOTE—See [Table 2](#) for the relative retention times.]

Suitability requirements

Resolution: NLT 5.0 between dopamine related compound B and dopamine related compound A, *System suitability solution*

Relative standard deviation: NMT 5.0% for dopamine related compound A, dopamine related compound B, and dopamine related compound C, *Standard solution*

Signal-to-noise ratio: NLT 20, *Sensitivity solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of dopamine related compound A, dopamine related compound B, and dopamine related compound C in the portion of Dopamine Hydrochloride taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of dopamine related compound A, dopamine related compound B, or dopamine related compound C from the *Sample solution*

r_s = peak response of dopamine related compound A, dopamine related compound B, or dopamine related compound C from the *Standard solution*

C_s = concentration of the [USP Dopamine Related Compound A RS](#), [USP Dopamine Related Compound B RS](#), or [USP Dopamine Related Compound C RS](#) in the *Standard solution* (mg/mL)

C_u = concentration of Dopamine Hydrochloride in the *Sample solution* (mg/mL)

Calculate the percentage of any unspecified impurity in the portion of Dopamine Hydrochloride taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

r_u = peak response of any unspecified impurity from the *Sample solution*

r_s = peak response of dopamine hydrochloride from the *Standard solution*

C_s = concentration of [USP Dopamine Hydrochloride RS](#) in the *Standard solution* (mg/mL)

C_u = concentration of Dopamine Hydrochloride in the *Sample solution* (mg/mL)

Acceptance criteria: See [Table 2](#). The reporting threshold is 0.05%.

Table 2

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Dopamine	1.0	—
Dopamine related compound B	2.1	0.1
Dopamine related compound A	2.8	0.1
Dopamine related compound C	4.2	0.1
Any unspecified impurity	—	0.10
Total impurities	—	0.2▲ (USP 1-Aug-2022)

SPECIFIC TESTS

Delete the following:

▲ [READILY CARBONIZABLE SUBSTANCES TEST \(271\)](#)

Sample solution: 100 mg of Dopamine Hydrochloride in 5 mL of [sulfuric acid](#)

Acceptance criteria: The solution has no more color than *Matching Fluid A* (see [Color and Achromicity \(631\)](#), [Color Determination and Standards](#)).▲ (USP 1-Aug-2022)

• [pH \(791\)](#)

Sample solution: 1 in 25

Acceptance criteria: 3.0–5.5

• [LOSS ON DRYING \(731\)](#)

Analysis: Dry at 105° for 2 h.

Acceptance criteria: NMT 0.5%

Delete the following:

▲ • CLARITY AND COLOR OF SOLUTION

Sample solution: 400 mg of Dopamine Hydrochloride in 10 mL of [sodium bisulfite solution](#) (1 in 1000)

Acceptance criteria: This solution is clear and colorless, or practically colorless.▲ (USP 1-Aug-2022)

ADDITIONAL REQUIREMENTS

Change to read:

- **PACKAGING AND STORAGE:** Preserve in tight containers. Store at ▲controlled▲ (USP 1-Aug-2022) room temperature.

Change to read:

• [USP REFERENCE STANDARDS \(11\)](#)

[USP Dopamine Hydrochloride RS](#)

▲ [USP Dopamine Related Compound A RS](#)

5-(2-Aminoethyl)-2-methoxyphenol.

C₉H₁₃NO₂

167.21

[USP Dopamine Related Compound B RS](#)

4-(2-Aminoethyl)-2-methoxyphenol.

C₉H₁₃NO₂

167.21

[USP Dopamine Related Compound C RS](#)

2-(3,4-Dimethoxyphenyl)ethan-1-amine.

C₁₀H₁₅NO₂

181.23▲ (USP 1-Aug-2022)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
DOPAMINE HYDROCHLORIDE	Documentary Standards Support	SM22020 Small Molecules 2

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 46(2)

Current DocID: GUID-7D8122C7-8455-42DA-B785-56C90D1B6E99_6_en-US

Previous DocID: GUID-7D8122C7-8455-42DA-B785-56C90D1B6E99_5_en-US

DOI: https://doi.org/10.31003/USPNF_M28010_06_01

DOI ref: [sm9m2](#)

OFFICIAL